| Abstrakt: |
Background: Mapping the mechanistic heterogeneity and multifactorial nature of Alzheimer's Disease (AD) is a key challenge for therapeutic development and the main reason why network biology and multi‐modal therapies begin to attract attention also in AD research. MiRNA‐targeted therapeutics are particularly suited for such purposes, as they regulate multiple components of several molecular cascades converging on disease‐relevant patho‐phenotypes. MicroRNA‐132 (miR‐132), a potent neuroimmune regulator, has been identified as the most robustly and significantly downregulated microRNA in the brain of AD patients and its deficiency has been functionally linked to amyloid deposition, TAU hyperphosphorylation, neuronal cell death and memory decline, in both human and rodents. Additionally, miR‐132 was recently identified as a potent regulator of adult hippocampal neurogenesis (AHN), exerting multilayered proneurogenic effects in adult neural stem cells and their progeny. Together, these observations suggest that miR‐132‐dependent network‐based gene regulation in human AD brain converges onto biological pathways that can drive disease endophenotypes. Direct miR‐132 infusion in the AD mouse brain can counteract several aspects of pathology, providing a proof‐of‐concept of its therapeutic relevance. Despite the great benefit of the multi‐targeting nature of microRNAs for treating multifactorial diseases such as AD, such approaches also entail the risk of on‐ and off‐ target toxicity, highlighting the importance of systematic genome‐wide targetome profiling. The complex multicellular miR‐132 targetome involved in AHN and the inflammatory response in AD remains elusive, and its mapping is a crucial requirement for therapeutic targeting. Method: In order to systematically profile the mechanisms underpinning the regulatory effects of miR‐132 in AD, we employed an RNA‐sequencing approach to assess transcriptomic responses to changes in the levels of miR‐132 in AD‐relevant study systems, such as human iPSC‐derived neurons and microglia‐like cells. Results: We identify novel miR‐132 targets with putative neuroimmune functions possibly involved in AD pathophysiology. Conclusion: Our results shed light on the involvement of miR‐132 in AD and further add to the systematic profiling of miR‐132 targetome, a prerequisite for successful translation of miR‐132 supplementation in AD. [ABSTRACT FROM AUTHOR] |
